"Our novel prostate cancer drug works by a unique mechanism of action," said study lead author Jeremy Jones, PhD, assistant professor ofmolecular pharmacologyat City of Hope, Beckman Research Institute, in Duarte, CA. "Thus, it has the potential to treat cancers resistant to currently approved ...
Substitution for these medications is recommended when possible or evaluate for loss of activity if medication is continued. Concomitant administration of Erleada with medications that are substrates of UDP-glucuronosyl transferase (UGT) can result in decreased exposure. Use caution if substrates of ...
This new medication can be considered a new standard for treatment of prostate cancer.Tsukagoshi SCancer Institute Japanese Foundation of Cancer Research.癌と化学療法Tsukagoshi, S. A new LH-RH agonist for treatment of prostate cancer, 3-month controlled-release formulation of goserelin acetate (...
Credit: Pixabay/CC0 Public Domain Cancer patients who receive radiation during their treatment—and about half do—may face a lesser-known challenge: bone loss. The vital treatment for cancers of the head and neck, breast, cervix, prostate, and even eyes can harm the cells that keep bones s...
Valproate is the most effective medication for generalised epilepsies, and several specific epilepsy syndromes. For some people, it will be the only medica
A US Food and Drug Administration (FDA) designation that expedites the FDA review process for a promising medication with the potential to address an unmet medical need for a serious or life-threatening condition with no adequate treatment or cure. Rights and permissions Reprints and permissions Ab...
(FDA) for a new indication for its oral hormonal medication bicalutamide (Casodex). The supplemental application asks the FDA to approve the use of bicalutamide (150 mg) monotherapy for the management of patients with locally advanced, nonmetastatic (stage T3-T4, NX, M0) prostate cancer. ...
leading to improved motor functions as assessed by North Star Ambulatory Assessment scores. Notably, the medication has demonstrated a high level of tolerability (Mendell et al.2023; Zaidman et al.2023). The most commonly reported AE include vomiting and nausea, pyrexia, and thrombocytopenia. The...
therapeutics: chemically synthesized small-molecule drugs that make up most of the market; and more expensive, protein-based biologics. Cellular therapy has now emerged as a third contender, setting the stage for powerful new vaccines, regenerative heart medication, and major advances in cancer ...
Abstral is approved for patients with cancer aged ≥18 years who already use opioid pain medication around the clock and are experiencing periodic breakthrough pain. The recommended initial dose of the drug is a single 100-μg tablet. If adequate analgesia is achieved within 30 minutes of admini...